This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Published July 12, 2026·Last reviewed August 4, 2026·Methodology v1.0

This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Liraglutide: uses, evidence, cost and safety

Quick answer

Liraglutide is a once-daily GLP-1 receptor agonist, FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management. It predates the weekly agonists and generally produces more modest average weight loss, but daily dosing gives some patients finer control over side effects.

The $449 tier has a condition. LillyDirect prices Zepbound at $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) a month under its self-pay programme. The $449 rate on 7.5 mg and above holds only if you refill within 45 days of your previous delivery. Miss that window and the refill is charged at the standard rate — reported at $499 to $699 depending on dose — before the programme rate resumes on the next order. Re-read at source 4 August 2026.

What Liraglutide is

Liraglutide is a glp-1 receptor agonist (daily). It is marketed as Victoza (type 2 diabetes), Saxenda (weight management). Liraglutide is a once-daily GLP-1 receptor agonist, FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management. It predates the weekly agonists and generally produces more modest average weight loss, but daily dosing gives some patients finer control over side effects.

Regulatory status

FDA-approved as a finished drug; now also available in generic versions.

How does it work?

Same GLP-1 receptor mechanism as semaglutide, but a shorter half-life requiring daily injection.

Clinical evidence

Average body-weight reduction in pivotal trials — Liraglutide

Mean percent body-weight change from controlled trials. Bars show trial averages over the study period; individual results vary widely and are not guaranteed. Values shown are percentage points.

The SCALE program supported Saxenda's weight-management indication, with mean weight loss generally in the 5–8% range — below the weekly agonists.

Pivotal trial evidence — mean body-weight change, with citations
Trial	Arm	Result	Duration	Comparator	Source
SURMOUNT-1	Tirzepatide 15 mg	−20.9%	72 weeks	Placebo −3.1%	NEJM 2022 (Jastreboff et al.)
SURMOUNT-1	Tirzepatide 10 mg	−19.5%	72 weeks		NEJM 2022
SURMOUNT-1	Tirzepatide 5 mg	−15.0%	72 weeks		NEJM 2022
SURMOUNT-5	Tirzepatide (max tolerated)	−20.2%	72 weeks	vs semaglutide −13.7%	NEJM 2025 (Aronne et al.)
STEP 1	Semaglutide 2.4 mg	−14.9%	68 weeks	Placebo −2.4%	NEJM 2021 (Wilding et al.)
STEP 8	Semaglutide 2.4 mg	−15.8%	68 weeks	vs liraglutide 3.0 mg −6.4%	JAMA 2022 (Rubino et al.)
SCALE	Liraglutide 3.0 mg	−8.0%	56 weeks	Placebo −2.6%	NEJM 2015
SELECT	Semaglutide 2.4 mg	20% MACE reduction	~40 months	Cardiovascular outcomes	NEJM 2023

Dosing and titration

See the FDA label for the approved dose schedule.

Reading trial numbersWeight-loss figures come from controlled trials in specific populations over defined periods. Individual results vary widely, and trial averages are not a promise of outcome.

Common and serious side effects

Nausea, diarrhea, constipation and headache; daily injection is the main practical drawback.

Warnings and contraindications

Same class boxed warning for thyroid C-cell tumors; same MTC/MEN 2 contraindication; not for use in pregnancy.

When to seek urgent careSeek urgent care for severe abdominal pain (possible pancreatitis), signs of an allergic reaction, or symptoms of gallbladder disease. Telehealth is not a substitute for emergency care.

Brand versus compounded liraglutide

Liraglutide is sold as an FDA-approved brand drug (Victoza (type 2 diabetes), Saxenda (weight management)) and, separately, as a compounded preparation through some telehealth programs. These are not regulatory equals.

What the FDA actually saysCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

We deliberately avoid the claim, common on competitor sites, that a compounded product's "safety profile mirrors" the brand. The molecule may be identical; the regulatory oversight, quality verification and manufacturing controls are not.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of August 4, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Brand vs compounded — monthly cost, verified August 4, 2026

Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.

For how to evaluate a compounding program, see how to verify a compounding pharmacy.

Frequently asked questions

Is Liraglutide FDA-approved?

FDA-approved as a finished drug; now also available in generic versions.

How does Liraglutide work?

Same GLP-1 receptor mechanism as semaglutide, but a shorter half-life requiring daily injection.

What are the most common side effects of Liraglutide?

Nausea, diarrhea, constipation and headache; daily injection is the main practical drawback.

Who should not take Liraglutide?

Same class boxed warning for thyroid C-cell tumors; same MTC/MEN 2 contraindication; not for use in pregnancy.

Is compounded Liraglutide the same as the brand version?

The active ingredient is the same molecule. However, compounded versions are not FDA-approved, the FDA does not verify their quality before marketing, and after the shortage resolved, routine compounding of this molecule became restricted. See our compounded liraglutide guide.

Sources

U.S. Food and Drug Administration — prescribing information and drug labels for Victoza (type 2 diabetes), Saxenda (weight management).
Pivotal randomized controlled trials as cited in the evidence section (SURMOUNT, SURPASS, STEP, SUSTAIN, SCALE as applicable).
CMS National Plan & Provider Enumeration System — clinician verification for reviewed providers.
ClinicalTrials.gov — trial registrations for investigational agents.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices — NovoCare and LillyDirect — were re-read on the manufacturers’ own published price guides on 4 August 2026. Figures captured from third-party provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row says so. We do not restamp a figure we have not re-read.